Fexofenadine vs placebo after STEMI to see if it helps heart healing

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter, double‑blind, randomized controlled trial in adults with STEMI who have undergone PCI. Participants receive either fexofenadine hydrochloride or placebo in addition to standard treatment, to assess safety and potential improvement in cardiac outcomes. The trial builds on preclinical data suggesting fexofenadine may reduce cardiac fibrosis and promote better heart function after myocardial injury. Outcomes focus on efficacy and safety signals during follow‑up in the acute post‑PCI period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ages above 18;
* Being able to verbally confirm understanding of the trial risks, benefits, and treatment options of receiving treatment with fexofenadine hydrochloride. He/she or his/her legal representative shall provide written informed consent before participating in the clinical trial.
* Meet the diagnostic criteria for STEMI, the diagnostic criteria includes:

  1. Clinical symptoms: ischemic chest pain lasting for over 30 minites;
  2. Elevated serum cTn: at least once higher than the upper limit of normal values (99th percentile of the reference upper limit);
  3. ST segment elevation: new ST segment elevation in two or more adjacent leads on the ECG;
* Emergency coronary angiography and revascularization should be performed;
* Ultrasonic cardiogram indicates regional wall motion abnormality, and transthoracic echocardiography shows LVEF ≤ 50% within 72 hours after revascularization.

Exclusion Criteria:

* Long term use of fexofenadine hydrochloride or other H1 receptor inhibitors;
* Previously suffered from myocardial infarction or received coronary artery bypass grafting;
* Patients with concomitant cardiomyopathy or valve disease;
* History of severe renal failure, estimated glomerular filtration rate (eGFR) \< 30ml/min;
* History of severe liver dysfunction;
* Concurrent severe infections, or liver/gallbladder obstruction, or history of malignant tumors;
* Currently receiving immunosuppressive therapy;
* Pregnant or potentially pregnant and breastfeeding women;
* Contraindications for fexofenadine hydrochloride or cardiac magnetic resonance examinations;
* Without obtaining written informed consent.
* Patients with hemodynamic instability.

Where it's running

• The 2nd Affiliated Hopital of Zhejiang University, School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Xinyang Hu, PhD — 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
• Study coordinator: Yinchuan Xu, PhD
• Email: lsyrmxyc@126.com
• Phone: 86-13968126628

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adenosine given before primary PCI to reduce no-reflow in STEMI patients.

  See if giving intracoronary adenosine before primary PCI lowers the chance of slow flow/no-reflow in adults with STEMI.

  Recruiting at 2 sites Phase 4 National Institute of Cardiovascular Diseases, Pakistan · Karachi, Sindh and 1 other locations · NCT07536802

• Using cardiac MRI and AI to predict outcomes after STEMI

  This project will try to use routine cardiac MRI scans plus AI to see if imaging features can predict long-term outcomes in people who had a STEMI treated with primary PCI.

  Recruiting Chinese PLA General Hospital · Beijing · NCT07072858

• Using beta-blockers for heart attack patients in intensive care

  This study is testing if the heart medication metoprolol can help heart attack patients in intensive care feel better and avoid worsening their condition.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT06967194

• Using an aspiration catheter for treating heart attacks

  This study tests whether using a special catheter can help remove blood clots from the heart arteries during a heart attack to improve blood flow and patient recovery.

  Recruiting BrosMed Medical Co., Ltd · Shanghai, Shanghai Municipality · NCT06951724

• Using machine learning to improve early diagnosis of acute cardiovascular conditions

  This study is testing a new tool that uses advanced computer technology to help doctors quickly and accurately diagnose serious heart problems in patients who come to the emergency room with chest pain or trouble breathing.

  Recruiting University Hospital, Basel, Switzerland · Basel · NCT06927791

• Administering adrenaline in STEMI patients during PCI to prevent no reflow

  This study tests if giving adrenaline during heart procedures can help STEMI patients avoid complications with blood flow without causing heart rhythm problems.

  Recruiting Phase 3 Ain Shams University · Cairo · NCT06847568

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.